


EBNA1-IN-SC7

Cat. No.:	HY-131236		
CAS No.:	324022-08-4		
Molecular Formula:	C ₂₀ H ₁₆ BrNO ₅ S		
Molecular Weight:	462.31		
Target:	EBV		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (216.31 mM); ultrasonic and warming and heat to 60°C

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1631 mL	10.8153 mL	21.6305 mL
	5 mM	0.4326 mL	2.1631 mL	4.3261 mL
	10 mM	0.2163 mL	1.0815 mL	2.1631 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (5.41 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

EBNA1-IN-SC7 (compound SC7) is a selective Epstein-Barr nuclear antigen 1 (EBNA1) inhibitor that interferes with EBNA1-DNA binding activity with an IC₅₀ value of 23 μM. EBNA1-IN-SC7 is used in EBV (Epstein-Barr virus)-related cancer research^[1].

In Vitro

EBNA1-IN-SC7 (compound SC7) (5 μM) can completely block transcriptional activation of EBNA1 and show a 60% inhibition of Zta (EBV-encoded b-zip DNA binding protein) trans-activation in HEK293T cells^[2].
EBNA1-IN-SC7 (compound SC7) (10 μM, 6 days) has no significant effect on EBV genome copy number of Raji Burkitt lymphoma cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Lijun Jiang, et al. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. *Theranostics*. 2018 Oct 22;8(19):5307-5319.
- [2]. Ning Li, et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. *PLoS One*. 2010 Apr 12;5(4):e10126.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA